Format

Send to

Choose Destination

Preclinical study of new TB drugs and drug combinations in mouse models.

Author information

1
Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850, USA. borisnikonenko@sequella.com

Abstract

Tuberculosis (TB) remains one of the leading infectious killers in the world. New anti-TB drugs and more effective drug combinations are urgently needed, particularly given the increasing incidence of drug-resistant TB and HIV-TB co-infection. This review describes the available mouse models of TB and describes their utility in the evaluation of new TB drug candidates and in the evaluation of the efficacy of new TB drug combinations. Some of the most recent patents on promising TB drug-candidates are also mentioned here.

PMID:
18673123
DOI:
10.2174/157489108784746579
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center